BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+4.43%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$956M
AUM Growth
+$956M
(+13%)
Cap. Flow
+$86.3M
Cap. Flow
% of AUM
9.03%
Top 10 Holdings %
Top 10 Hldgs %
34.18%
Holding
136
New
4
Increased
64
Reduced
26
Closed
5
Top Buys
| 1 |
Illumina
ILMN
|
$11M |
| 2 |
Align Technology
ALGN
|
$10.5M |
| 3 |
CELG
Celgene Corp
CELG
|
$10.3M |
| 4 |
Elevance Health
ELV
|
$9.07M |
| 5 |
Gilead Sciences
GILD
|
$7.35M |
Top Sells
| 1 |
Medtronic
MDT
|
$6.88M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$5.81M |
| 3 |
Cigna
CI
|
$5.21M |
| 4 |
Centene
CNC
|
$4.92M |
| 5 |
BCR
CR Bard Inc.
BCR
|
$4.66M |
Sector Composition
| 1 | Healthcare | 94.19% |
| 2 | Financials | 0.94% |
| 3 | Industrials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Viatris
VTRS
$12.3B
| $5.68M | 0.59% | 181,200 -82,000 | -31% | -$2.57M |
|
|
CERN
52
DELISTED
Cerner Corp
CERN
| $5.31M | 0.56% | 74,500 | – | – |
|
|
GNMK
53
DELISTED
GenMark Diagnostics, Inc
GNMK
| $5.04M | 0.53% | 523,677 +118,499 | +29% | +$1.14M |
|
54
Thermo Fisher Scientific
TMO
$186B
| $4.88M | 0.51% | 25,808 +11,208 | +77% | +$2.12M |
|
|
EGRX
55
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $4.86M | 0.51% | 81,550 -50,440 | -38% | -$3.01M |
|
56
BioMarin Pharmaceuticals
BMRN
$11.2B
| $4.54M | 0.48% | 48,800 -16,200 | -25% | -$1.51M |
|
57
Acadia Pharmaceuticals
ACAD
$4.38B
| $4.41M | 0.46% | 117,000 -69,000 | -37% | -$2.6M |
|
|
AGN
58
DELISTED
Allergan plc
AGN
| $4.2M | 0.44% | 20,500 -8,500 | -29% | -$1.74M |
|
59
Johnson & Johnson
JNJ
$427B
| $4.1M | 0.43% | 31,500 | – | – |
|
60
Perrigo
PRGO
$3.27B
| $3.93M | 0.41% | 46,468 -50,000 | -52% | -$4.23M |
|
61
ResMed
RMD
$40.2B
| $3.62M | 0.38% | 47,000 +10,900 | +30% | +$839K |
|
|
BLUE
62
DELISTED
bluebird bio
BLUE
| $3.45M | 0.36% | 25,100 +3,000 | +14% | +$412K |
|
63
Neurocrine Biosciences
NBIX
$13.8B
| $3.43M | 0.36% | 56,000 +9,000 | +19% | +$552K |
|
64
Dentsply Sirona
XRAY
$2.85B
| $3.26M | 0.34% | 54,500 +4,000 | +8% | +$239K |
|
|
ESRX
65
DELISTED
Express Scripts Holding Company
ESRX
| $3.13M | 0.33% | 49,500 | – | – |
|
66
Henry Schein
HSIC
$8.44B
| $3.12M | 0.33% | +38,000 | New | +$3.12M |
|
67
Agios Pharmaceuticals
AGIO
$2.19B
| $3M | 0.31% | 45,000 | – | – |
|
68
iShares Biotechnology ETF
IBB
$5.6B
| $3M | 0.31% | 9,000 +2,000 | +29% | +$667K |
|
69
Molina Healthcare
MOH
$9.8B
| $2.99M | 0.31% | 43,500 +27,000 | +164% | +$1.86M |
|
70
Nektar Therapeutics
NKTR
$568M
| $2.95M | 0.31% | 123,000 +80,000 | +186% | +$1.92M |
|
71
Alkermes
ALKS
$4.78B
| $2.85M | 0.3% | 56,100 -81,500 | -59% | -$4.14M |
|
72
McKesson
MCK
$85.4B
| $2.77M | 0.29% | 18,000 | – | – |
|
|
NUVA
73
DELISTED
NuVasive, Inc.
NUVA
| $2.56M | 0.27% | 46,204 +10,900 | +31% | +$604K |
|
74
United Therapeutics
UTHR
$13.8B
| $2.53M | 0.26% | 21,600 +13,800 | +177% | +$1.62M |
|
75
Teleflex
TFX
$5.59B
| $2.47M | 0.26% | 10,200 +3,200 | +46% | +$774K |
|